An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

NCT01924793 Phase 2 COMPLETED

This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.

Details

Lead sponsor	Ansun Biopharma, Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	23
Start date	2013-08
Completion	2017-05

Conditions

• Parainfluenza

Interventions

• DAS181-F02 Dry Powder in Bulk
• DAS181-F02 Nebulized Formulation Inhaled Dose

Primary outcomes

• Cumulative incidence and severity of AEs, SAEs, and lab abnormalities as a measure of safety and tolerability. — 2 years

Countries

United States